CAR-T plus dasatinib for hard-to-treat B-cell cancers
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This early study tests a cancer-fighting treatment that uses CAR-T cells together with dasatinib for people whose B-cell cancers have come back or did not respond. It aims to improve control of the cancer in cases that are often resistant to standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these blood cancers: CD19+ ALL, CD19+ non-Hodgkin lymphoma, or BCMA+ multiple myeloma
- Your cancer is “relapsed or refractory,” meaning it came back or didn’t respond well to standard or follow-up treatments
- Your organ tests are within limits (especially bilirubin, liver enzymes ALT/AST, and kidney creatinine)
- Your heart function is strong enough (left heart pumping strength, LVEF, is at least 50%)
- You do not have uncontrolled infections, and you can breathe well (oxygen level in room air is at least 92%)
- You must be healthy enough overall (ECOG 0 to 2) and able to join the study (consent)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a type of immune treatment (CAR-T cells) for blood cancers that have come back or did not respond after standard treatments. It is for tumors that have CD19 on their cells, aiming to reduce the cancer and improve remission chances.
This Phase 1/2 study tests a BCMA-targeting CAR-T cell therapy for people with relapsed or refractory multiple myeloma or related plasma cell diseases. It may help by using your own immune cells, engineered to recognize a specific target on cancer cells.
This trial tests a type of immunotherapy called CAR-T cells that target two proteins (CD19 and CD22) on cancer cells. It may be an option for adults with B-cell acute lymphoblastic leukemia (ALL) or B-cell non-Hodgkin lymphoma (NHL) that has come back or not responded to earlier treatments.
This trial tests a new CAR-T treatment that targets three proteins on lymphoma cells (CD19, CD22, and BCMA). It is for people with certain types of B-cell lymphoma that have come back or are not responding to standard treatments.
This trial tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells. It is for people with certain B-cell blood cancers that have come back or not responded to treatment, and aims to see if this therapy can help control the cancer.
This early-phase trial tests a type of immunotherapy called anti-CD19 CAR-T cells. These are specially engineered immune cells that seek out and destroy cancer cells with a marker called CD19 on their surface. It is for people with B-cell cancers (leukemia or lymphoma) that have not responded to or come back after standard treatments.
Hear when a new Multiple Myeloma in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.